ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

JAMIE GAUDIN MSN, APRN, ACNP-BC

At A Glance: This Prescriber in 2012

Nurse Practitioner, Acute Care

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,444Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 25

$7 Total Retail Price of All Prescriptions

Rank: 25 out of 25

146 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
0% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

20% of this provider’s 146 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

28% of this provider’s 146 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Risky Drugs to Seniors

0% of this provider’s 7,670 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$0 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

58 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
CITALOPRAM HBR 296 259 1 15
SENNA PLUS 261 247 2 29
ASPIRIN EC 245 208 3 30
8 HOUR PAIN RELIEVER 228 217 10 4 35
OMEPRAZOLE 194 159 5 7
CERTAVITE SENIOR-ANTIOXIDANT 185 165 10 6 41
FUROSEMIDE 177 177 7 1
AMLODIPINE BESYLATE 161 118 8 2
CALCIUM 600 + VIT D 160 152 9 48
HYDROCODONE-ACETAMINOPHEN 145 135 S3 10 26
SIMVASTATIN 128 124 11 6
LISINOPRIL 122 107 12 5
PREDNISONE 116 109 13 39
RISPERIDONE 111 111 14 64
ROPINIROLE HCL 109 97 15 65
CARVEDILOL 104 85 16 13
BUMETANIDE 102 102 17 68
LORATADINE 101 100 18 69
MIRTAZAPINE 91 84 19 71
TRAMADOL HCL 89 80 20 18
ATORVASTATIN CALCIUM 71 58 21 10
ZOLPIDEM TARTRATE 71 52 21 46
GABAPENTIN 71 71 21 20
PRAVASTATIN SODIUM 67 59 24 3
BUPROPION XL 67 67 24 83
GLIMEPIRIDE 67 57 24 83
ALPRAZOLAM 65 29 27 44
POTASSIUM CHLORIDE 64 62 28 14
MORPHINE SULFATE ER 64 57 S2 28 88
METHOTREXATE 64 64 28 88
LEVOTHYROXINE SODIUM 63 63 31 4
TRAZODONE HCL 62 62 32 45
HYDROCHLOROTHIAZIDE 60 58 33 11
METOPROLOL SUCCINATE 60 59 33 9
CALCIUM 500 + VIT D 59 59 35 90
CETIRIZINE HCL 58 57 36 91
PANTOPRAZOLE SODIUM 57 54 37 33
SERTRALINE HCL 57 57 37 51
CARBIDOPA-LEVODOPA 53 53 39 48
WARFARIN SODIUM 52 50 40 21
TUSSIN DM 52 50 10 40 101
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 24, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.